Generic Medicine Info
Indications and Dosage
Adult: As immediate release tab: Initially, 1 mg daily at night. May increase to 2 mg daily after 3-4 wk, if necessary.
Child: ≥12 yr Same as adult dose.

ADHD (attention deficit hyperactivity disorder)
Child: 6-17 yr As extended-release tab: Initially, 1 mg once daily, increased if necessary by increments of not more than 1 mg per wk. Maintenance: 0.05-0.12 mg/kg daily, according to response and tolerability. Max: 6-12 yr 4 mg daily; 13-17 yr 7 mg daily.
Special Precautions
Patient w/ history of hypotension, heart block, bradycardia, CV disease, history of syncope or conditions which may predispose them to syncope (e.g. dehydration), history of QT prolongation, risk factors for torsade de pointes. Avoid abrupt withdrawal. Renal or hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Somnolence, bradycardia, hypotension, abdominal pain, dry mouth, dizziness, headache, constipation, depression, anxiety, fatigue, nausea, vomiting, diarrhoea, enuresis, impotence, orthostatic hypotension, decreased appetite, insomnia, nightmare, sedation, lethargy, irritability, rash.
Patient Counseling Information
This drug may cause dizziness, somnolence, and syncope, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor heart rate, BP and consider ECG prior to initiation.
Symptoms: Drowsiness, lethargy, bradycardia, resp depression, coma and hypotension. Management: Supportive treatment. Perform gastric lavage if ingestion is recent. Admin of activated charcoal may be considered.
Drug Interactions
Additive effect w/ diuretics, other antihypertensives, CNS depressants. Phenobarbital and phenytoin may decrease elimination half-life and plasma concentration of guanfacine for renally impaired patients. Additive sedative effect w/ centrally active depressants (e.g. phenothiazines, barbiturates, benzodiazepines). Increased plasma concentrations w/ CYP3A4/5 inhibitors (e.g. ketoconazole). Decreased rate and extent of exposure w/ CYP3A4 inducers (e.g. rifampicin).
Food Interaction
Avoid high-fat meal due to increased exposure (extended-release). Increased plasma concentrations w/ grapefruit juice. Additive sedative effect w/ alcohol.
Description: Guanfacine is a selective α2A-adrenoceptor agonist that reduces sympathetic nerve impulse from the vasomotor centre to the heart and blood vessels, resulting in a decrease in peripheral vascular resistance, BP and heart rate.
Duration: Antihypertensive effect: 24 hr.
Absorption: Rapidly absorbed. Bioavailability: Approx 80%. Time to peak plasma concentration: 1-4 hr.
Distribution: Extensively distributed in tissues. Plasma protein binding: Approx 70%.
Metabolism: Metabolised rapidly in the liver via CYP3A4/5-mediated oxidation, w/ subsequent sulfation and glucuronidation.
Excretion: Via urine, as unchanged drug (approx 50%) and metabolites. Elimination half-life: 10-30 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Guanfacine, CID=3519, (accessed on Jan. 23, 2020)

Store between 20-25˚C.
MIMS Class
Other Antihypertensives / Other CNS Drugs & Agents for ADHD
ATC Classification
C02AC02 - guanfacine ; Belongs to the class of imidazoline receptor agonists, centrally-acting antiadrenergic agents. Used in the treatment of hypertension.
Anon. Guanfacine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 27/05/2016.

Buckingham R (ed). Guanfacine hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 27/05/2016.

Guanfacine Hydrochloride Tablet (Mylan Pharmaceuticals Inc. DailyMed. Source: U.S. National Library of Medicine. Accessed 27/05/2016.

Guanfacine Tablet, Extended Release (AvKARE, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 27/05/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Guanfacine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 27/05/2016.

Disclaimer: This information is independently developed by MIMS based on Guanfacine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in